MetaCap

10x Genomics Inc. Class A (TXG)

NASDAQ: TXGIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

51.80-5.58 (-9.72%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TXG stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.52
52-week range
15.18 – 102.81
Day range
51.30 – 56.44
Volume / Avg
3.23M / 3.36M
Beta
—

52-week range

$15.18$102.81

TXG stock today

10x Genomics (TXG) closed at $51.80 on Nov 20, down 9.72% (-$5.58), versus the S&P 500's 3.70% decline. Shares are 49.6% below their 52-week high of $102.81, set on Oct 6, 2026 and 241.2% above the 52-week low of $15.18, in the middle of the past year's range. TXG is up 217.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 182.4%.

10x Genomics has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About 10x Genomics

Company profile

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Dr. Serge Saxonov Ph.D.
Headquarters
Pleasanton, CA
Employees
1,178
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, 10x Genomics generated $642.8 million in revenue, up 5.2% from fiscal 2024. 10x Genomics reported a net loss of $43.5 million, compared with a loss of $182.6 million a year earlier. Gross margin was 69.1% (up from 67.9%) and operating margin -9.5%.

10x Genomics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$642.82M$610.78M$618.73M$516.41M$490.49M
Growth+5.25%-1.28%+19.81%+5.28%+64.13%
Net income$-43.54M$-182.63M$-255.10M$-166.00M$-58.22M
EPS (diluted)$-0.35$-1.52$-2.18$-1.46$-0.53

Analyst forecast

Forecast

Consensus (17 analysts)

buy

Avg. price target

$68.14+31.54%

  • Strong buy 1
  • Buy 5
  • Hold 11
  • Sell 0
  • Strong sell 0

Target range

Low $50.00High $100.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.22 vs $-0.29
Surprise
+24.14%

TXG news

All TXG news

10x Genomics peers

Industrials sector
TXG peer companies
CompanyPrice% ChgMarket capCompare
BRKRBruker Corporation56.46-9.08%$8.62Bvs TXG
BIOBio-Rad Laboratories Inc. Class A358.90-2.34%$9.65Bvs TXG
AVTRAvantor Inc.14.84-1.85%$10.06Bvs TXG
ALMRAlamar Biosciences Inc.26.48-7.67%$1.84Bvs TXG
CTKBCytek Biosciences Inc.6.12-3.16%$800.40Mvs TXG
PACBPacific Biosciences of California Inc.1.63-7.39%$508.95Mvs TXG
NAUTNautilus Biotechnology Inc.2.12-2.30%$270.03Mvs TXG
LABStandard BioTools Inc.0.631+2.82%$249.11Mvs TXG

Indexes, lists and sector

10x Genomics stock FAQ

What is 10x Genomics's stock price today?

TXG last traded at $51.80 as of Nov 20, 4:00 PM EST, down 9.72% on the day. Prices are delayed at least 15 minutes.

Who is 10x Genomics's CEO?

Dr. Serge Saxonov Ph.D. is the chief executive officer of 10x Genomics Inc. Class A, which has about 1,178 employees.

What is the TXG 52-week high?

The 52-week high for TXG is $102.81 and the 52-week low is $15.18. The stock is currently 49.6% below its high.

Compare TXG